Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, ABI Dispute over Joint Genotyping Deal Sent to Arbitration

NEW YORK, Dec. 22 (GenomeWeb News) - The case that Illumina brought against Applied Biosystems just over one year ago for breach of a joint development for genotyping systems has been sent to arbitration, Illumina said late Friday.

 

A San Diego superior court judge has directed the parties to an arbitration procedure, Illumina said.

 

The dispute arises out of an agreement the companies penned in 1999 to jointly commercialize a genotyping system. In July 2002, following delays in the development of the joint system, Illumina went ahead and launched its own BeadArray SNP genotyping system.

 

Applied Biosystems first filed suit against Illumina last year for patent infringement related to its oligo-ligation assay. ABI also alleged that Illumina was the one in breach of contract of the genotyping development deal, and sought arbitration.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.